Open AccessCombined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
Author(s) -
Paola Queirolo,
Francesco Spagnolo,
Virginia Picasso,
Laura Spanò,
Enrica T. Tanda,
Valeria Fontana,
Laura Giorello,
Domenico Franco Merlo,
Ester Simeone,
Antonio Grimaldi,
Marcello Curvietto,
Michele Del Vecchio,
Paolo Bruzzi,
Paolo A. Ascierto
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.10589
Subject(s) - vemurafenib , medicine , clinical endpoint , melanoma , progression free survival , oncology , metastatic melanoma , phases of clinical research , refractory (planetary science) , clinical trial , gastroenterology , chemotherapy , cancer research , cancer , physics , astrobiology
BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.